Degree of hermeticity of a multicompartment compliance aid: Implications for the quality of professional pharmaceutical services by Modamio Charles, Pilar et al.
 Research Signpost 
 37/661 (2), Fort P.O. 
 Trivandrum-695 023  
 Kerala, India 
 
 
Recent Advances in Pharmaceutical Sciences IV, 2014: 133-142 ISBN: 978-81-308-0554-2 
Editors: Diego Muñoz-Torrero, Manuel Vázquez-Carrera and Joan Estelrich 
 
9. Degree of hermeticity of a 
multicompartment compliance aid: 
Implications for the quality of professional 
pharmaceutical services    
 
Pilar Modamio, Héctor R. Loscertales, Antonio J. Braza                         
Gonzalo Tobaruela, Cecilia F. Lastra and Eduardo L. Mariño1 
Clinical Pharmacy and Pharmacotherapy Unit, Department of Pharmacy and                             
Pharmaceutical Technology, Faculty of Pharmacy, University of Barcelona 
 E-08028, Barcelona, Spain 
 
Abstract. A multicompartment compliance aid (MCA) is a blister-
type repackaging system that aims to facilitate drug administration 
and thereby increase patient adherence. One of the characteristics 
of the MCA that should be taken into account is the moisture 
permeability, since this atmospheric condition is one of the most 
important factors that can modify the stability of medicines. In the 
current paper we report the moisture permeability tests performed 
on a MCA according to the US Pharmacopeia. This information on 
the suitability of the device will help pharmacists implement a 
high-quality professional service.  
 
Introduction 
 
      The scale of the problem posed by low levels of adherence to drug 
therapy represents a major concern for all health systems.  A report published 
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by the WHO indicates that in developed countries, 50% of patients who 
suffer from chronic conditions fail to comply; and in developing countries 
this figure is even higher [1]. 
 Despite the fact that problems of adherence occur independently of the 
condition, type of patient and socioeconomic level, geriatric patients are more 
vulnerable to incorrect use of medicines; this is mainly due to a reduction in 
their functional capacity and the large number of drugs that they take long 
term [2]. According to Kendrick and Bayne [3], expected adherence to a 
treatment regimen for a person of advanced age who takes just one medicine 
is 65%; this is reduced to 54% when the patient takes four medicines; and it 
drops to below 7% as the number of medicines increases. In addition, the lack 
of adherence to the dosage schedule on the part of the geriatric patient is 
directly related to periods of hospitalisation [4]. Moreover, the current 
demographic situation, with a constantly increasing life expectancy, means 
that the incidence and prevalence of complex chronic conditions also 
increase, and it is these patients who consume large numbers of medicines 
[5]. Therefore, it is becoming ever more important to use tools and develop 
plans of action aimed at improving adherence and contributing to the 
increased safety, effectiveness and efficiency of drugs and of healthcare 
resources in general [6]. 
 
1. Multicompartment compliance aid 
  
 A multicompartment compliance aid (MCA), also called a monitored 
dosage system, is a blister-pack system into which drugs are re-packaged and 
which is used to organise all the solid medicines that a given patient takes 
over a week, following the prescribed dosage schedule. In accordance with 
the manufacturer’s certificate, the MCA is safe, hygienic and made of 
innocuous materials that do not interact at all with the medicines. The MCA 
is a tool designed to facilitate the administration of medication and therefore 
to increase patient compliance, as well as to reduce drug administration 
errors. The Pharmaceutical Services Negotiating Committee, which 
represents community pharmacies in England and Wales, already 
recommends the use and monitoring of this type of pack for all patients with 
problems when it comes to taking their medication [7]. Similarly, in 2005, the 
Australian Government’s Department of Health and Ageing, under the 4th 
Community Pharmacy Agreement, founded a specific MCA programme with 
the idea of reducing hospitalisations related to medication and improve 
treatment adherence in the population where it is required [8]. 
 In Spain, Royal Decree Law 9/2011 of 19th August consisting of 
measures to improve the quality and cohesion of the national health system 
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[9] modified Section 1 of Article 84 of Law 29/2006 of 26th July regarding 
the guarantees and rational use of medicines and healthcare products [10]. 
The regulations pertaining to MCA use currently declaim: ―In pharmacies, 
the pharmacists, being those responsible for the dispensing of medicines to 
citizens, will encourage compliance with the schedule established by the 
physician responsible for prescribing medicines to the patient, and will aid in 
treatment adherence through pharmaceutical care procedures that contribute 
to ensuring efficacy and safety. The pharmacist will also take part in a series 
of activities designed to enhance the rational use of medicines, in particular 
through informed dispensing to the patient. Once the medicine has been 
supplied, the pharmacist may provide monitored dosage systems to patients 
who ask for them, in order to improve treatment compliance, for those 
treatments and with the attendant conditions and requirements that the 
competent health authorities establish.‖ In September 2012, the first guide to 
drug therapy adherence with MCA use was published under the coordination 
of the regional Council of Pharmaceutical Colleges in Catalonia [11]. More 
recently, in May 2013, at the national level the General Pharmaceutical   
Council approved distribution of the Standard MCA Working Procedure [12]. 
The elements necessary for the pharmacist in a community pharmacy to 
provide professional MCA service are defined in both documents.  
 
2. Selection of the multicomparment compliance aid 
 
 The MCA is required to conform to a series of characteristics, including: 
―… preserving the stability of the medication they contain; … The 
manufacturer must guarantee (through supplying the corresponding 
certificate) that it is made of innocuous materials that do not interact with the 
contents; … The degree of hermeticity specified in the US Pharmacopeia 
(USP)‖. However, despite the fact that different devices are available on the 
market, is the pharmacist, or in general the healthcare professional, who 
decides which to choose to work with, as well as assigning a use date after  
re-packaging the medication into the MCA [13]. 
 One of the characteristics of the MCA that should be taken into account 
is the degree of protection from moisture, since this atmospheric condition is 
one of the most important factors that can modify the stability of medicines. 
In accordance with the USP [14], the so-called moisture permeability test 
establishes whether a MCA meets the hermeticity or moisture impermeability 
requirements specified for this type of device (Class B). In the current paper 
we report the results of moisture permeability tests performed on a MCA. 
This information on the suitability of the device will help healthcare 
professionals implement a high-quality professional service. 
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3. Moisture permeability test 
 
 The material used to perform the moisture permeability test included: the 
MCA and a support for the repackaging supplied directly by the distributor 
(Fig. 1). 
 It consists of a lamina of polyethylene terephthalate plastic with 28 
compartments or blisters (divided into four vertical columns —to indicate the 
doses—and seven horizontal rows —to indicate the days of the week) and a 
piece of cardboard. One side of the piece of cardboard has a sheet of a 
greaseproof aluminium compound stuck to it covered in a water-based self-
adhesive material to strongly hold in place or glue porous supports to plastic 
surfaces, which is protected by what appears to be silicon-coated paper. It is 
cold sealed using a suitable support which the plastic lamina is placed on. 
The piece of cardboard is placed on top of the plastic lamina (once the 
silicon-covered paper has been removed), in such a way that the side with the 
aluminium is in contact with the plastic lamina, sealing the two parts of the 
system by applying pressure to the cardboard. In this way the containers or 
blisters of the device are individually sealed.  
 We also used: desiccant pellets (TK-1002L), 8 mm in diameter × 10 mm, 
in accordance with the specifications of the USP, supplied by Medical 
Packaging Inc.; two stability chambers, Memmert mod.100 and Kötterman 
mod. 2736, one to perform the test and one to activate the pellets; a precision 
balance (Precisa mod.125 A) to weigh both the test MCA and the controls; a 
desiccator, to keep the pellets isolated from atmospheric humidity once 
activated; a maximum and minimum mercury thermometer (Celsius®) to 
monitor temperature in the chamber, and a digital maximum and minimum 
 
     
 
Figure 1. Multicompartment compliance aid (MCA) assayed (a) and support used for 
repackaging (b). 
(b)  
(a)  
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thermo-hygrometer (TFA®) to monitor the humidity. Solutions of 35 g of 
NaCl (Panreac, Castellar del Vallés, Barcelona) per 100 ml of water were 
prepared to maintain the relative humidity (RH) constant within the chamber 
(75% ± 3%).  
 The test was performed in accordance with the USP, section 671 [14] of 
which details the method to be followed to determine the moisture permeability 
of devices (packs) that incorporate a number of single-dose individually-sealed 
blisters (Method II). The packs are classified, according to the results, from the 
least to the most permeable as Class A, Class B, Class C and Class D. A 
package is designated Class A if no packs tested exceeds 0.5 mg/day in average 
blister moisture permeation rate; it is designated Class B if no pack tested 
exceeds 5 mg/day in average blister moisture permeation rate; it is designated 
Class C if no pack tested exceeds 20 mg/day in average blister moisture 
permeation rate; and it is designated Class D if the packs tested meet none of 
the above average blister moisture permeation rate requirements. The test was 
performed on 12 MCA for each Class (A, B, C or D), depending on the 
moisture permeability. The procedure was the same for all of them:  
 
- 6 of them were filled at random with the desiccant pellets (test MCA) 
and the other 6 were tested as controls (control MCA) (Fig. 2). 
- All the packs were stored at 23ºC ± 2ºC and 75% ± 3% RH for 24 h, at 
which time they were removed from the chamber and left to equilibrate 
for 45 min.  
- The initial weighing was then carried out (the test MCA were weighed 
individually and the control MCA together to find their average weight) 
and then they were again placed into the chamber, for the appropriate 
time for each Class (24 h for Class D, 48 h for Class C, 7 days for class B 
and at least 28 days for Class A). If, during the procedure, any pellet 
turned pink or there was a 10% increase in the average weight of the 
pellets in any test pack, the assay was considered over, with the prior 
determination being taken as valid.  
- The average rate of moisture permeation, in mg/day, for each container 
or blister in each MCA was calculated by applying the following 
formula:  
 
(1/NX) [(Wf–Wi) – (Cf–Ci)] 
 
where:  
 
 N is the number of days expired (beginning after the initial 24-hour 
equilibration period);  
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 X is the number of separately sealed units per pack (in the MCA assayed 
is 28);  
 (Wf –Wi) is the difference, in mg, between the final and initial weights of 
each test pack; and  
 (Cf –Ci) is the difference, in mg, between the average final and average 
initial weights of the control packs. 
 
          
 
Figure 2. Test multicompartment compliance aid (MCA) (a) and control MCA (b). 
 
4. Results of the permeability test  
 
 In accordance with the method described and based on the design of the 
study, the results are shown in Tables 1-4. 
 
Table 1. Moisture permeability test for Class D packs. 
 
Test MCA Control MCA 
Average rate of  
moisture permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
 Initial average weight  
 (mg) 
Final average  
weight (mg) 
32210 32363 
26892 
 
26905 
 
5.000 
32344 32479 4.357 
32080 32217 4.429 
32810 32933 3.929 
32510 32650 4.536 
32707 32862 5.071 
 
 
(b)  (a)  
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Table 2. Moisture permeability test for Class C packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32712 32983 
26690 
 
26751 
 
3.750 
32380 32611 3.036 
32854 33115 3.571 
32448 32660 2.696 
31822 32043 2.857 
32018 32221 2.536 
 
Table 3. Moisture permeability test for Class B packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32894 33573 
26705 
 
26798 
 
2.990 
32791 33430 2.786 
32574 33190 2.668 
32786 33405 2.684 
32593 33201 2.628 
32844 33476 2.750 
 
Table 4. Moisture permeability test for Class A packs. 
 
Test MCA Control MCA Average rate of  
moisture 
permeation 
(mg/day) 
Initial weight 
 (mg) 
Final weight 
 (mg) 
Initial average  
weight (mg) 
Final average  
weight (mg) 
32094 32899 
26692 
 
26839 
 
0.839 
32915 33792 0.931 
32561 33374 0.849 
32688 33306 0.601 
32769 33428 0.653 
32714 33547 0.875 
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5. Implications for the quality of professional pharmaceutical 
services 
 
 Royal Decree Law 9/2011 [9] authorizes Spanish community 
pharmacists to prepare MCA for those patients who need them, and therefore 
it foresees that the use of this type of device will spread over the coming 
years, and moreover that this should happen in a standard way throughout the 
whole country. Taking into account that one of the basic functions of a MCA 
is to ensure that the medicines remain in similar conditions to those of their 
primary packaging, it is of utmost importance to know the different degrees 
of protection against environmental conditions that the MCA available on the 
market guarantee. The permeability test for packs that incorporate a number 
of individually sealed single-dose blisters is the first test that should be 
performed on this type of devices to establish whether they meet the 
requirements of hermeticity given in the pharmacopeia. The type of material 
the MCA is made of together with the loading process and the type of seal 
will determine the degree of protection against moisture the pack offers [15]. 
The results of the present study are based on the method described above 
with the objective of guaranteeing the highest standard for a professional 
service that uses these MCA. The results show that the MCA tested can be 
considered as Class D packs, since none of the average blister moisture 
permeation speeds was more than 20 mg/day after 24 h. They also meet the 
requirements for Class C and Class B packs, since all the average blister 
moisture permeation speeds were less than 20 mg/day after 48 h, and less 
than 5 mg/day after 7 days, respectively. However, they did not meet the 
Class A pack requirements, as over the 28 days of study all the average 
moisture permeation speeds were more than 0.5 mg/day. Despite the fact that 
the MCA studied here did not offer maximum barrier protection against 
atmospheric moisture (Class A), it does meet the conditions of hermeticity 
that the pharmacopeia demands for this type of packs (Class B). 
 The technical stage of re-packaging medicines into a MCA involves 
removing the medicine from its primary packaging of presentation, which 
annuls the manufacturer’s stability guarantee, and it is the responsibility of 
the pharmacist who prepares and dispenses it to establish a use date for the 
MCA once it has been loaded. That date indicates the moment after which the 
MCA should not be used (and therefore the medicines re-packaged) and in 
order to establish that date it is important to take into account, among others, 
the following information [13,15]: the nature of the medicine re-packaged 
into the MCA, available information about drug stability, the primary 
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packaging in which it was presented by the manufacturer and its expiry date, 
the characteristics of the MCA into which it has been loaded, the expected 
storage conditions the medicines will be exposed to, and the useful life the 
MCA is expected to have (Fig. 3). 
 
What type of MCA to use?
Pharmacist’s decision
Characteristics of the MCA: 
Properties of protection 
(humidity, temperature,…)
Useful life 
of the 
MCA 
The nature of 
the medicine 
repackaged
Primary packaging and 
expiry date of the 
medicine
Expected storage 
conditions of the 
MCA
 
 
Figure 3. Some relevant aspects to consider by pharmacists in the decision of what 
type of multicompartment compliance aid (MCA) to use. 
 
6. Conclusions 
 
 We performed a study to determine the degree of hermeticity of a cold-
sealed MCA. In accordance with the USP and the method detailed above, we can 
conclude that the MCA tested meets the hermeticity requirements specified by 
the pharmacopeia for this type of device.  
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